Shattuck Labs reports Q2 2025 cash balance of $50.5mln, eyes Phase 1 trial for SL-325.

• Shattuck Labs submits IND application for SL-325 in Q3 2025. • Phase 1 clinical trial for SL-325 expected to begin in Q3 2025. • Cash balance at $50.5 million at end of Q2 2025. • Aggregate proceeds from private placement expected to fund operations into 2029.

Shattuck Labs, Inc. (NASDAQ: STTK), a biotechnology company focusing on the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors, has reported significant progress in its clinical pipeline. The company recently submitted an Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers, with clearance expected in the third quarter of 2025 [1].

Shattuck Labs is on track to dose the first participant in the Phase 1 clinical trial for SL-325 in the third quarter of 2025. The trial will assess safety, tolerability, immunogenicity, and pharmacokinetics of SL-325, aiming to determine the recommended Phase 2 dose and dosing schedule. The company expects to complete Phase 1 enrollment by the second quarter of 2026 [1].

Financial highlights for the second quarter ended June 30, 2025, include a cash balance of approximately $50.5 million, down from $105.3 million as of June 30, 2024. Research and Development (R&D) expenses were $8.7 million, and General and Administrative (G&A) expenses were $4.4 million. The company reported a net loss of $12.5 million for the quarter, or $0.24 per basic and diluted share, compared to $21.6 million for the same period in 2024 [1].

Shattuck Labs has also recently completed an oversubscribed private placement, led by OrbiMed, with aggregate proceeds of up to $103 million, less offering expenses. The company expects these funds to support its operations into 2029. The closing of the private placement is contingent upon the IND clearance for SL-325 and satisfaction of other customary closing conditions [1].

The company's lead product candidate, SL-325, is a potentially first-in-class DR3 blocking antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck Labs plans to nominate a lead bispecific candidate from its preclinical pipeline in 2025 [1].

Shattuck Labs participated in several industry conferences, including the 24th Annual Needham Virtual Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism. The company is scheduled to attend the H.C. Wainwright 27th Annual Global Investment Conference in September 2025 [1].

References:
[1] https://www.globenewswire.com/news-release/2025/08/14/3133267/0/en/Shattuck-Labs-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Business-Highlights.html